非小细胞肺癌ERCC1、TS的表达及临床意义

Expression and clinical significance of ERCC1、TS protein in non-small cell lung cancer

目的研究非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中核苷酸切除修复交叉互补基因1(ERCC1)、胸苷酸合酶(TS)的表达及临床意义。方法采用免疫组化法测定51例患者NSCLC组织中的ERCC1、TS的表达情况。结果非小细胞肺癌组织中ERCC1、TS的阳性表达率分别为49.0%和60.8%,与患者的年龄、性别、组织学类型、临床分期、淋巴结有无转移均无明显相关性(P>0.05);TS与分化程度有关(P<0.05)。ERCC1、TS表达呈正相关(P<0.01)。结论 NSCLC组织中ERCC1、TS高表达,有望成为NSCLC个体化治疗有预测价值的分子标志物。

Objective To study the expression of ERCC1、TS protein in non-small cell lung cancer,and explore its clinical significance.Methods The expression of ERCC1 and TS protein in 51 patients with NSCLC was detected by immunohistochemical methods.Results The positive expression of ERCC1 and TS protein in 51 patients with NSCLC was 49.0% and 60.8% respectively which has no significant correlation with the patients＇age,gender,histological types,clinical stages and lymph node metastasis status（P0.05）.The positive expression of TS protein was related to differentiation degree（P0.05）.The expression of ERCC1 and TS was positively correlated（P0.01）.Conclusion The higher expression levels of ERCC1 and TS in NSCLC may become predictive biomarkers in individualized treatment of NSCLC.